Atlas Antibodies has released novel monoclonal antibodies for female genital tract pathology

Our company has now released new PrecisA MonoclonalTM antibodies targeting 23 proteins relevant to ovarian cancers (such as high and low-grade serous, endometrioid, clear cell, and mucinous carcinomas), with diagnostic and prognostic value validated in IHC, WB and ICC-IF.

September is Gynecologic Cancer Awareness month. Gynecologic cancers are cancers originating in the female reproductive organs. The 5 main types of gynecologic cancers are cervical, ovarian, uterine, vaginal, and vulvar. Of these, ovarian cancer is the deadliest form of gynecological cancers causing more deaths than any other cancer of the female reproductive system. The Centers for Disease Control and Prevention (CDC) estimates every 7 minutes someone is diagnosed with one of these cancers.

Ovarian cancer is the 8th most common cancer among women and the 5th cause of cancer-related death in women with a 5-year survival of only 30–50%. It still remains the deadliest gynecologic malignancy in the western world and is most often diagnosed at a rarely curable late stage.

An early detection of ovarian cancer would in fact improve the 5-year survival rate, from close to 90% in stage I compared to only 20% when the cancer is discovered in stage IV.

This September Atlas Antibodies is raising awareness for Gynecologic Cancers by releasing 23 new monoclonal antibodies to aid in the diagnosis of these cancers, especially ovarian cancer.

The primary tumor biopsy followed by an immunohistochemical analysis (IHC) of the tissue remain the gold standard to identify the molecular alterations associated with the tumors and identify potentially prognostic and predictive biomarkers for an early-stage detection.

Atlas Antibodies has now released new PrecisA MonoclonalTM antibodies targeting 23 proteins relevant to ovarian cancers (such as high and low-grade serous, endometrioid, clear cell, and mucinous carcinomas), with diagnostic and prognostic value validated in IHC, WB and ICC-IF.

Join us in supporting gynecologic cancer research with the markers featured below.

Among the new monoclonals released are:

The immunohistochemistry on ovarian cancer tissues using the Anti-CLDN3 monoclonal antibody (AMAb91835)
Figure 1: Claudin-3 is a prognostic marker for epithelial ovarian high-grade serous carcinoma (HGSC). The immunohistochemistry on ovarian cancer tissues using the Anti-CLDN3 monoclonal antibody (AMAb91835) reveals intense staining in high-grade (left) compared to low-grade (right) serous ovarian carcinoma.
The immunohistochemistry on ovarian cancer tissues using the Anti-CD44 monoclonal antibody (AMAb91847)
Figure 2: CD44 is a prognostic endometrioid ovarian cancer (EC) marker. The immunohistochemistry on ovarian cancer tissues using the Anti-CD44 monoclonal antibody (AMAb91847) reveals positive staining in endometrioid (left) compared to papillary (right) ovarian carcinoma.
Immunohistochemistry on ovarian cancer tissues using the Anti-NAPSA monoclonal antibody (AMAb91825)
Figure 3: NAPSA is a diagnostic marker for ovarian clear cell carcinoma (CCC). Immunohistochemistry on ovarian cancer tissues using the Anti-NAPSA monoclonal antibody (AMAb91825). Positive staining is visible in brown in clear cell ovarian carcinoma (CCC, left) but not in high-grade serous ovarian carcinoma (HGSC, middle) and endometrial ovarian adenocarcinoma (EC, right).

Stay tuned for more details!

Read more about Atlas Antibodies’ PrecisA Monoclonals™.